Analysis of Endocan Levels in Hypertensive Patients as Risk Factors of Chronic Kidney Disease

Suryani Jamal, Uleng Bahrun, Ibrahim Abdul Samad, Fitriani Mangarengi, Hasyim Kasim, Ilham Jaya Patellongi

Abstract


This study aimed to analyze endocan levels as a marker of endothelial dysfunction in the control group, patients with
stage I hypertension, stage II hypertension, and patients with end-stage renal disease. Endocan levels were measured with
ESM-1 (endocan) kit by Enzyme-Linked Immunosorbent Assay (ELISA) method. This study used a cross-sectional method
and was conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from September
to October 2017. There were 83 samples in this study, consisting of 12 samples in the control group, 22 samples of stage I
hypertension, 28 samples of stage II hypertension, and 21 samples of end-stage renal disease aged 20-90 years old. This
study showed significantly higher endocan levels in patients with stage II hypertension and end-stage renal disease
(p< 0.05). Endocan levels were significantly higher (p<0.05) in patients with end-stage renal disease compared with the
control group and patients with stage I hypertension; but not significantly higher (p > 0.05) compared to patients with stage
II hypertension. Also, the median of endocan levels in patients with the end-stage renal disease was higher (309,850 ng/L)
compared to patients with stage II hypertension (273,050 ng/L).


Keywords


Endocan, endothelial dysfunction, hypertension, chronic kidney disease

Full Text:

PDF

References


JNC VII. The seventh report of the Joint National

Committee on prevention, detection, evaluation, and

treatment of high blood pressure. JAMA, 2003; 289:

-71.

CDC. National chronic kidney disease fact sheet:

General information and national estimates on chronic

kidney disease in the United States. Atlanta: US

Department of Health and Human Services. Centers

for Disease Control and Prevention. 2014. Available at:

http://www.cdc.gov/diabetes/pubs/factsheets/kidne

y.htm (accessed 15 February, 2017)

KDIGO. Clinical practice guideline for the evaluation

and management of chronic kidney disease. Kidney

International Supplements, 2013; 3(1): 63-73.

Basic Health Research, Health Research and

Development Agency Ministry of Health Republic of

Indonesia. 2013; 95-103.

Kali A, Shetty KSR. Endocan: A novel circulating

proteoglycan. Indian J Pharmacol, 2012; 46 (6):

-583.

Kang YH, Ji NY, Han SR, Lee CI, Kim JW, et al. ESM-1

regulates cell growth and metastatic process through

activation of NF- k B in colorectal cancer. Cell Signal,

; 24(10): 1940-9.

Afsar B, Takir M, Kostek O, Covic A, Kanbay M.

Endocan: A new molecule playing a role in the

development of hypertension and chronic kidney

disease. The Journal of Clinical Hypertension, 2014; 16

(12): 914-916.

Human ESM-1 (Endothelial Cell Specific Molecule 1)

ELISA Kit. Available at: http://www.elabscience.com

(accessed 2 April, 2017).

Bakri S, Lawrence GS. Genetics of hypertension. In:

Lubis HR. Hypertension and kidney: In the framework

of full service Prof. Dr. Harun Rasyid Lubis, Sp.PD-KGH.

Field. USU Press, 2008; 19-31.

Balta S, Mikhailidis DP, Demirkol S, Ozturk C,

Kurtoglu E, et al. Endocan-a novel inflammatory

indicator in newly diagnosed patients with

hypertension: A pilot study. Angiology, 2013; 1-5.

Campbell D, Weir MR. Defining, treating, and

understanding chronic kidney disease-a complex

disorder. The Journal of Clinical Hypertension, 2015;

(7): 514-27.

Chen J, Hamm LL, Mohler ER, Hudaihed A, Arora R,

et al. Interrelationship of multiple endothelial

dysfunction biomarkers with chronic kidney disease.

PLos One, 2015; 10(7): 1-10.

Glancy MR. Endocan as a potential diagnostic or

prognostic biomarker for chronic kidney disease.

Kidney International, 2014; 86: 1079-81.

Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R,

et al. Serum endocan level and the severity of coronary

artery disease: A pilot study. Angiology, 2015;

(8):727-31.

Lee HG, Choi HY, Bae JS. Endocan as a potential

diagnostic or prognostic biomarker for chronic kidney

disease. Kidney International, 2014; 86: 1079-81.

Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU,

et al. Plasma endocan levels associate with

inflammation, vascular abnormalities, cardiovascular

events, and survival in chronic kidney disease. Kidney

Int, 2014; 86: 1213-20.

Rahmania L, Cortes DO, Irazabal M, Mendoza M,

Santacruz C, et al. Elevated endocan levels are

associated with development of renal failure in ARDS

patients. Intensive Care Med Exp, 2015; 3(1): A264.

Su YH, Shu KH, Hu CP, Cheng CH, Wu MJ, et al. Serum

endocan correlated with stage of chronic kidney

disease and deterioration in renal transplant

recipients. Transplant Pro, 2014; 46(2): 323-7.

Whayne TF. Endocan in hypertension and

cardiovascular disease. Angiology, 2016; 20: 1-3.




DOI: http://dx.doi.org/10.24293/ijcpml.v27i1.1571

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.